Literature DB >> 25766947

Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.

Timothy P Murphy1, Donald E Cutlip2, Judith G Regensteiner3, Emile R Mohler4, David J Cohen5, Matthew R Reynolds6, Joseph M Massaro7, Beth A Lewis8, Joselyn Cerezo9, Niki C Oldenburg10, Claudia C Thum6, Michael R Jaff11, Anthony J Comerota12, Michael W Steffes10, Ingrid H Abrahamsen6, Suzanne Goldberg13, Alan T Hirsch10.   

Abstract

BACKGROUND: Treatment for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent revascularization (ST). However, supervised exercise (SE) is known to provide comparable short-term (6-month) improvements in functional status and quality of life. Longer-term outcomes are not known.
OBJECTIVES: The goal of this study was to report the longer-term (18-month) efficacy of SE compared with ST and optimal medical care (OMC).
METHODS: Of 111 patients with aortoiliac PAD randomly assigned to receive OMC, OMC plus SE, or OMC plus ST, 79 completed the 18-month clinical and treadmill follow-up assessment. SE consisted of 6 months of SE and an additional year of telephone-based exercise counseling. Primary clinical outcomes included objective treadmill-based walking performance and subjective quality of life.
RESULTS: Peak walking time improved from baseline to 18 months for both SE (5.0 ± 5.4 min) and ST (3.2 ± 4.7 min) significantly more than for OMC (0.2 ± 2.1 min; p < 0.001 and p = 0.04, respectively). The difference between SE and ST was not significant (p = 0.16). Improvement in claudication onset time was greater for SE compared with OMC, but not for ST compared with OMC. Many disease-specific quality-of-life scales demonstrated durable improvements that were greater for ST compared with SE or OMC.
CONCLUSIONS: Both SE and ST had better 18-month outcomes than OMC. SE and ST provided comparable durable improvement in functional status and in quality of life up to 18 months. The durability of claudication exercise interventions merits its consideration as a primary PAD claudication treatment.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  angioplasty; ankle-brachial index; cilostazol; exercise rehabilitation; quality of life; walking

Mesh:

Year:  2015        PMID: 25766947      PMCID: PMC5278564          DOI: 10.1016/j.jacc.2014.12.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

1.  Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.

Authors:  Joanne M Murabito; Jane C Evans; Kenneth Nieto; Martin G Larson; Daniel Levy; Peter W f Wilson
Journal:  Am Heart J       Date:  2002-06       Impact factor: 4.749

2.  Primary end-point error.

Authors:  Timothy P Murphy; Sandra Spronk; Maria de Ridder; Emmanuel M E H Lesaffre
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

Review 3.  Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.

Authors:  B L W Bendermacher; E M Willigendael; J A W Teijink; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Sham procedure versus usual care as the control in clinical trials of devices: which is better?

Authors:  E Rand Sutherland
Journal:  Proc Am Thorac Soc       Date:  2007-10-01

5.  Peripheral arterial disease in the elderly: The Rotterdam Study.

Authors:  W T Meijer; A W Hoes; D Rutgers; M L Bots; A Hofman; D E Grobbee
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

6.  Value of a supervised exercise program for the therapy of arterial claudication.

Authors:  R B Patterson; B Pinto; B Marcus; A Colucci; T Braun; M Roberts
Journal:  J Vasc Surg       Date:  1997-02       Impact factor: 4.268

7.  Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease.

Authors:  F A K Mazari; J A Khan; D Carradice; N Samuel; M N A Abdul Rahman; S Gulati; H L D Lee; T A Mehta; P T McCollum; I C Chetter
Journal:  Br J Surg       Date:  2011-10-21       Impact factor: 6.939

8.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

9.  Exercise training improves functional status in patients with peripheral arterial disease.

Authors:  J G Regensteiner; J F Steiner; W R Hiatt
Journal:  J Vasc Surg       Date:  1996-01       Impact factor: 4.268

10.  Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study.

Authors:  Ulf G Bronas; Alan T Hirsch; Timothy Murphy; Dalynn Badenhop; Tracie C Collins; Jonathan K Ehrman; Abby G Ershow; Beth Lewis; Diane J Treat-Jacobson; M Eileen Walsh; Niki Oldenburg; Judith G Regensteiner
Journal:  Vasc Med       Date:  2009-11       Impact factor: 3.239

View more
  43 in total

1.  An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.).

Authors:  Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren
Journal:  Ann Vasc Dis       Date:  2015-10-23

2.  Novel magnetic resonance imaging end points for physiologic studies in peripheral arterial disease: elegance versus practicality.

Authors:  Christopher M Kramer
Journal:  Circ Cardiovasc Imaging       Date:  2015-04       Impact factor: 7.792

Review 3.  Intermittent Claudication and Asymptomatic Peripheral Arterial Disease.

Authors:  Gerhard Rümenapf; Stephan Morbach; Andrej Schmidt; Martin Sigl
Journal:  Dtsch Arztebl Int       Date:  2020-03-13       Impact factor: 5.594

Review 4.  Clinical Assessment of Peripheral Arterial Disease in the Office: What Do the Guidelines Say?

Authors:  Srini Tummala; Derek Scherbel
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 5.  TOWARDS THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE.

Authors:  Brian H Annex; George A Beller
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 6.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

7.  Supervised walking exercise therapy improves gait biomechanics in patients with peripheral artery disease.

Authors:  Molly N Schieber; Iraklis I Pipinos; Jason M Johanning; George P Casale; Mark A Williams; Holly K DeSpiegelaere; Benjamin Senderling; Sara A Myers
Journal:  J Vasc Surg       Date:  2019-08-20       Impact factor: 4.268

8.  Exercise Rehabilitation for Peripheral Artery Disease: A REVIEW.

Authors:  Mary M McDermott
Journal:  J Cardiopulm Rehabil Prev       Date:  2018-03       Impact factor: 2.081

9.  Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.

Authors:  Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

Review 10.  Intermittent claudication due to peripheral artery disease: best modern medical and endovascular therapeutic approaches.

Authors:  Taisei Kobayashi; Sahil A Parikh; Jay Giri
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.